EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSXMAG00000006524
Gene Symbol: PSMD12
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSXMAG00000018394
Gene Symbol: PSMD13
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSXMAG00000001819
Gene Symbol: PSMD14
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSXMAG00000008179
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSXMAG00000001995
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSXMAG00000009179
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSXMAG00000007685
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSXMAG00000011738
Gene Symbol: LOC102217550
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSXMAG00000000491
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSXMAG00000000493
Gene Symbol: LOC102236097
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSXMAG00000007637
Gene Symbol: LOC102219594
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSXMAG00000014653
Gene Symbol: LOC102219510
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).